Zhejiang Hisoar Pharmaceutical Co Ltd (002099.SZ) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · China · ISIN CNE000001PY2

Price
5.77 CNY
Market cap
9.34 bn CNY
P/E (2025)
–
P/S (2025)
5.02
Dividend yield
0.00 %
Net margin
-4.89 %
Return on equity (ROE)
-1.81 %
Return on assets (ROA)
-1.24 %

Zhejiang Hisoar Pharmaceutical Co Ltd financials

Fiscal year20242025
Revenue1.94 bn CNY1.86 bn CNY
Gross profit343.72 m CNY454.76 m CNY
Operating income-336.14 m CNY-11.28 m CNY
EBIT-131.53 m CNY-56.84 m CNY
Net income-330.27 m CNY-91.08 m CNY
Diluted EPS – continuing operations-0.21 CNY-0.06 CNY

Full history since 2003, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Zhejiang Hisoar Pharmaceutical Co Ltd

Zhejiang Hisoar Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates in China and internationally. It operates through Pharmaceutical Industry, Dye Industry, and Others segments. The company offers antibiotics, cardiovascular drugs, hypoglycemic agents, formulations, and fine chemicals. It also provides dyes and pigment intermediates; environmental protection-related equipment; medical chemical supplies and appliances; and other chemical intermediates. In addition, the company engages in technology research and development; trading; hazardous waste treatment; equity investment; technical consulting and other consulting services; and venture capital activities. It exports its products to approximately 30 countries, including Europe, America, and Asia. Zhejiang Hisoar Pharmaceutical Co., Ltd. was founded in 1966 and is headquartered in Taizhou, China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.